Pharmacologic prevention of vascular access stenosis

Current Opinion in Nephrology and Hypertension

Volumn 8, Issue 5, 1999, Pages 569-572

  Himmelfarb, Jonathan ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL AFFECTING AGENT; CLOPIDOGREL; HEPARINOID;

COST EFFECTIVENESS ANALYSIS; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THROMBOSIS; VASCULAR ACCESS;

ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; ASPIRIN; BLOOD VESSELS; CATHETERS, INDWELLING; CONSTRICTION, PATHOLOGIC; DIPYRIDAMOLE; GENE THERAPY; HUMANS; RENAL DIALYSIS;

EID: 0033404599     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199909000-00006     Document Type: Review

References (29)

1. 1 Hakim RM, Himmelfarb J. Hemodialysis access failure. A call to action. Kidney Int 1998; 54:1029-1040. An overall review of the issues related to dialysis vascular access.
2. 2 Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996; 7:523-535.
3. 3 Shaffer D. Catheter-related sepsis complicating long term, tunneled central venous dialysis catheters: management by guidewire exchange. Am J Kidney Dis 1995; 25:593-596.
4. 4 Kovalik EC, Raymond JR, Albers FA, Berkoben M, Montella B, Conlon PJ. A clustering of epidural abscesses in chronic hemodialysis patients: risks of salvaging access catheters in cases ot infection. J Am Soc Nephrol 1996; 7:2264-2267.
5. 5 Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D. Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty. Radiology 1995; 195:135-139.
6. 6 Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC. Intimal fibromuscular hyperplasia at the venous anastamosis of PTFE grafts in hemodialysis patients. Circulation 1989; 80:1726-1736.
7. 7 Moncada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978; i:1286-1298.
8. 8 Neville RF, Sidawy AN. Myointimal hyperplasia: basic science and clinical considerations. Semin Vasc Surg 1998; 11:142-148.
9. 9 Quinones-Baldrich WJ. Myointimal hyperplasia: a lesion. In: pharmacological suppression of intimal hyperplasia. Georgetown TX: R.G. Landes Company, 1993, p. 1.
10. 10 Dicorleto PE, Bowen-Pope DF. Cultured endothelial cells produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 1983; 80:1919.
11. 11 Zarins CK, Zatina MA, Giddens DP, et al. Shear stress regulation of artery lumen diameter in experimental atherogenesis. J Vasc Surg 1987; 5:413-420.
12. 12 Grotendorst GR, Chang T, Seppa HEJ, Kleinman HK, Martin GR. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol 1982; 113:261-266.
13. 13 Jawein A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992; 89:507-511.
14. 14 Loscalzo J, Handin RJ. Chapter 25, Platelet glycocalicin. Methods in Enzymology 1992; 215:289-293.
15. 15 Beer JH, Buchi L, Steiner RW. Glycocalicin: a new assay - the normal plasma level and its potential usefulness in selected diseases. Blood 1994; 83:691-702.
16. 16 Michelson AD, Loscalzo J, Melnick B, Coller BS, Handin RI. Partial characterization of a binding site for von Willebrand factor on glycocalicin. Blood 1994; 67:19-26.
17. 17 Jandrot-Perrus M, Clemetson KJ, Huisse MG, Guillin MC. Thrombin interaction with platelet glycoprotein Ib: effect of glycocalicin on thrombin specificity. Blood 1992; 80:2781-2786.
18. 18 Harlan JM. Leukocyte-endothelial interactions. Blood 1985; 65:513-525.
19. 19 Butcher EC. Cellular and molecular mechanisms that direct leukocyte traffic. Am J Pathol 1990; 136:3-11.
20. 20 Quinones-Baldrich WJ. The role of anti-inflammatory agents in the control of intimal hyperplasia. In: pharmacological suppression of intimal hyperplasia. Edited by Quinones-Baldrich WJ. Georgetown, TX: R.G. Landes Company, 1993, p. 22.
21. 21 Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Antiplatelet therapy in graft thrombosis: results of a prospective, randomized double-blind study. Kidney Int 1994; 45:1477-1483.
22. 22 Harvey R, Bredenberg CE, Couper L, Himmelfarb J. Aspirin enhances platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Vasc Surg 1997; 25:689-695.
23. 23 Himmelfarb J, Couper L. Dipyridamole inhibits PDGF-and bFGF-induced vascular smooth muscle cell proliferation. Kidney Int 1997; 52:1671-1677.
24. 24 Lindsey WH, Davis PT. Facial keloid: a 15 year experience. Arch Otolaryngol Head Neck Surg 1998; 123:397-400.
25. 25 Waksman R, Robinson KA, Crocker IR, Gravanis MB, Cipolla GD, King SBI. Endovascular low-dose irradiation inhibits neointimal formation after coronary artery balloon injury in swine: a possible role for radiation therapy in restenosis prevention. Circulation 1995; 91:1533-1539.
26. 26 Fareh J, Martel R, Kermani P, Leclerc G. Cellular effects of beta-particle delivery on vascular smooth muscle cells and endothelical cells: a dose response study. Circulation 1999; 99:1477-1484.
27. 27 Teirstein PS, Massullo V, Jani S, Popma JJ, Mitnz GS, Russo RJ, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. New Engl J Med 1997; 1997:1697-1703.
28. 28 Wong FK, Kwok PC, Ngan RK, Wong RK, Wong K, Chan S, Chau K, Li C. Prevention of restenosis of central venous stricture after percutaneous transluminar angioplasty and endovascular stenting by brachytherapy. Kidney Int 1999; 55:742-743.
29. 29 Sukhatme V. Vascular access stenosis: prospects for prevention and therapy. Kidney Int 1996; 49:1161-1174.